Larimar Therapeutics, Inc.

NASDAQ: LRMR · Healthcare · Biotechnology

PublicHQ Bala Cynwyd, PA · MontgomeryCIK 0001374690Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

39D

FH 34DQ 40GM —SS 62

v0.1 · 55/100 weight · provisional

↑ market scale, Altman-Z · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$165.7M

Employees

as of 2026-08-13

Market cap

$454.0M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02019

Net income-$165.7M-$165.7M2025

Operating income-$172.5M-$172.5M2025

Total assets$145.8M$145.8M2025

Liabilities$67.8M$67.8M2025

Equity$78.1M$78.1M2025

Revenue trend

FY2018 – FY2019 · USD

FY18

FY19

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Larimar Therapeutics, Inc.’s revenue?

Larimar Therapeutics, Inc. booked $0 in FY2019 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Contineum Therapeutics, Inc.57C Nika Pharmaceuticals Inc.29D Benitec Biopharma Inc.47D Compass Therapeutics, Inc.50D Rocket Pharmaceuticals, Inc.53D Palisade Bio, Inc.71B

Neighbors

Montgomery →

Cencora, Inc.$321.3B84B+Toll Brothers, Inc.$11.0B69B SEI Investments Company$2.3B82B+Madrigal Pharmaceuticals, Inc.$958.4M64C Essential Utilities, Inc.$2.5B70B Globus Medical, Inc.$2.9B86A

Key facts

CEOCarole S. Ben-Maimon

SectorHealthcare

IndustryBiotechnology

HeadquartersBala Cynwyd, PA

ExchangeNASDAQ: LRMR

Employees71

IPO date2014-06-19

Latest filings

10-Q2026-08-04 8-K2026-08-04 8-K2026-06-29 8-K2026-05-19 8-K2026-05-14 10-Q2026-05-14 DEF 14A2026-04-20 8-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.